More horror from the usual suspects:
Why Pfizer Stopped COVID Vax Trial
July 11, 2023
Story at-a-glance
- In February 2021, Pfizer launched a randomized, placebo-controlled, observer-blind study to evaluate the safety of its COVID-19 shot — BNT162b2 — in healthy pregnant women
- The injections were set to take place between 24 and 34 weeks’ gestation, with participants randomized 1-to-1 to receive a COVID-19 shot or placebo
- The study was initially set to enroll 4,000 women, but Pfizer only signed up 349, then stopped enrollment entirely
- The CDC’s widespread endorsement of COVID-19 shots for pregnant women before the study was completed may have negated the need for the trial
- Pfizer stated that because so many pregnant women had already gone ahead and gotten the shot, due to the government’s endorsement, enrollment dropped and there was no reason to move ahead with the study
No randomized trial data are available for use of the COVID-19 shot in pregnant women, and Pfizer cut its pregnancy trial short.1 But this doesn’t stop the U.S. Centers for Disease Control and Prevention from recommending COVID-19 injections for everyone 6 months and older, including “people who are pregnant, breastfeeding, trying to get pregnant now, or those who might become pregnant in the future.”2
“Not having any good data didn’t seem to bother the CDC,” Dr. Martin Makary, a professor at Johns Hopkins University School of Medicine, wrote in Tablet.3 He and a team of scientists petitioned the U.S. Food and Drug Administration to add a disclaimer to the shot’s label about the lack of trial data on its safety in pregnant women. The FDA declined, stating that this information wouldn’t be relevant.
Pregnant women, however, do need to know about the shot’s lack of testing during pregnancy — it’s the foundation of informed consent. They’d also likely be interested to know why Pfizer stopped its pregnancy trial early and has yet to make the results it did find public.
Pfizer Stopped COVID Jab Pregnancy Trial, Withholds Data
Continued on PDF below: